Overview
Oncology healthcare professionals who treat patients with lung cancer have an increasing array of diagnostic and therapeutic tools at their disposal. These include the use of immunotherapy and targeted therapy in early-stage and locally advanced disease, as well as in metastatic lung cancer. Additionally, new classes of agents have become available, such as bispecific antibodies and antibody-drug conjugates. These developments have the potential to improve outcomes for patients with lung cancer, but also bring new considerations for implementation, including adequate testing and adverse event management.
The 27th Annual International Lung Cancer Congress® will distill the latest data on targeted agents, immunotherapy, surgery, and radiation oncology for the management of lung cancer. This event also will include a special visionary session with the annual Addario Keynote Lecture and an expert panel discussion on coming trends in lung cancer therapy over the next decade. As in previous years, cutting-edge lectures, multidisciplinary case-based tumor boards, and question-and-answer sessions will allow participants to engage with international and national experts as they share their perspectives and personal experiences of clinical challenges and ongoing controversies in lung cancer management.
Learning Objectives
Upon completion of this activity, learners will be better able to:
- Describe the role of biomarkers and testing strategies to optimize and personalize treatment selection in patients with lung cancer
- Analyze recent clinical trial evidence as well as ongoing trials for the management of patients with lung cancer
- Formulate approaches to integrate monotherapy and combination immunotherapeutic approaches in the management of patients with lung cancer
- Develop strategies to integrate targeted and cytotoxic agents for the management of patients with lung cancer
- Discuss approaches to address disparities in care for patients with lung cancer
Program Co-Chairs
Roy S. Herbst, MD, PhD; Sandip Patel, MD; Heather Wakelee, MD, FASCO
To view full profile, click on the Program Co-Chairs tab above.
This activity is supported by an educational grant from Partner Therapeutics, Inc.
Additional support for the Spotlight CE Session is provided by an educational grant from AbbVie, Inc.
PER is proud to partner with Lungevity, GO2 for Lung Cancer, Addario Lung Cancer Medical Institute (ALCMI), and International Association For the Study of Lung Cancer(IASLC).
